New Challenges of Treatment for Locally Advanced Head and Neck Cancers in the Covid-19 Pandemic Era

Locally advanced head and neck cancer is a unique challenge for cancer management in the Covid-19 situation. The negative consequences of delaying radio-chemotherapy treatment make it necessary to prioritize these patients, the continuation of radiotherapy being indicated even if SARS-CoV-2 infectio...

Full description

Bibliographic Details
Main Authors: Camil Ciprian Mireștean, Anda Crișan, Adina Mitrea, Călin Buzea, Roxana Irina Iancu, Dragoș Petru Teodor Iancu
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/10/4/587
id doaj-8041b67bd0064c51884312f72b92b8af
record_format Article
spelling doaj-8041b67bd0064c51884312f72b92b8af2021-02-05T00:04:18ZengMDPI AGJournal of Clinical Medicine2077-03832021-02-011058758710.3390/jcm10040587New Challenges of Treatment for Locally Advanced Head and Neck Cancers in the Covid-19 Pandemic EraCamil Ciprian Mireștean0Anda Crișan1Adina Mitrea2Călin Buzea3Roxana Irina Iancu4Dragoș Petru Teodor Iancu5Department of Oncology and Radiotherapy, University of Medicine and Pharmacy Craiova, 200349 Craiova, RomaniaDepartment of Oncology and Radiotherapy, University of Medicine and Pharmacy Craiova, 200349 Craiova, RomaniaCounty Clinical Emergency Hospital Craiova, 200642 Craiova, RomaniaNational Institute of Research and Development for Technical Physics, 700050 Iași, RomaniaDepartment of Oral Pathology, Gr. T. Popa, University of Medicine and Pharmacy, 700115 Iaşi, RomaniaDepartment of Oncology and Radiotherapy, “Gr. T. Popa” University of Medicine and Pharmacy, 700115 Iaşi, RomaniaLocally advanced head and neck cancer is a unique challenge for cancer management in the Covid-19 situation. The negative consequences of delaying radio-chemotherapy treatment make it necessary to prioritize these patients, the continuation of radiotherapy being indicated even if SARS-CoV-2 infection is confirmed in the case of patients with moderate and mild symptoms. For an early scenario, the standard chemo-radiotherapy using simultaneous integrated boost (SIB) technique is the preferred option, because it reduces the overall treatment time. For a late scenario with limited resources, hypo-fractionated treatment, with possible omission of chemotherapy for elderly patients and for those who have comorbidities, is recommended. Concurrent chemotherapy is controversial for dose values >2.4 Gy per fraction. The implementation of hypo-fractionated regimens should be based on a careful assessment of dose-volume constraints for organs at risks (OARs), using recommendations from clinical trials or dose conversion based on the linear-quadratic (LQ) model. Induction chemotherapy is not considered the optimal solution in this situation because of the risk of immunosuppression even though in selected groups of patients TPF regimen may bring benefits. Although the MACH-NC meta-analysis of chemotherapy in head and neck cancers did not demonstrate the superiority of induction chemotherapy over concurrent chemoradiotherapy, an induction regimen could be considered for cases with an increased risk of metastasis even in the case of a possible Covid-19 pandemic scenario.https://www.mdpi.com/2077-0383/10/4/587head and neck cancernon-surgicalradiotherapychemotherapyCovid-19
collection DOAJ
language English
format Article
sources DOAJ
author Camil Ciprian Mireștean
Anda Crișan
Adina Mitrea
Călin Buzea
Roxana Irina Iancu
Dragoș Petru Teodor Iancu
spellingShingle Camil Ciprian Mireștean
Anda Crișan
Adina Mitrea
Călin Buzea
Roxana Irina Iancu
Dragoș Petru Teodor Iancu
New Challenges of Treatment for Locally Advanced Head and Neck Cancers in the Covid-19 Pandemic Era
Journal of Clinical Medicine
head and neck cancer
non-surgical
radiotherapy
chemotherapy
Covid-19
author_facet Camil Ciprian Mireștean
Anda Crișan
Adina Mitrea
Călin Buzea
Roxana Irina Iancu
Dragoș Petru Teodor Iancu
author_sort Camil Ciprian Mireștean
title New Challenges of Treatment for Locally Advanced Head and Neck Cancers in the Covid-19 Pandemic Era
title_short New Challenges of Treatment for Locally Advanced Head and Neck Cancers in the Covid-19 Pandemic Era
title_full New Challenges of Treatment for Locally Advanced Head and Neck Cancers in the Covid-19 Pandemic Era
title_fullStr New Challenges of Treatment for Locally Advanced Head and Neck Cancers in the Covid-19 Pandemic Era
title_full_unstemmed New Challenges of Treatment for Locally Advanced Head and Neck Cancers in the Covid-19 Pandemic Era
title_sort new challenges of treatment for locally advanced head and neck cancers in the covid-19 pandemic era
publisher MDPI AG
series Journal of Clinical Medicine
issn 2077-0383
publishDate 2021-02-01
description Locally advanced head and neck cancer is a unique challenge for cancer management in the Covid-19 situation. The negative consequences of delaying radio-chemotherapy treatment make it necessary to prioritize these patients, the continuation of radiotherapy being indicated even if SARS-CoV-2 infection is confirmed in the case of patients with moderate and mild symptoms. For an early scenario, the standard chemo-radiotherapy using simultaneous integrated boost (SIB) technique is the preferred option, because it reduces the overall treatment time. For a late scenario with limited resources, hypo-fractionated treatment, with possible omission of chemotherapy for elderly patients and for those who have comorbidities, is recommended. Concurrent chemotherapy is controversial for dose values >2.4 Gy per fraction. The implementation of hypo-fractionated regimens should be based on a careful assessment of dose-volume constraints for organs at risks (OARs), using recommendations from clinical trials or dose conversion based on the linear-quadratic (LQ) model. Induction chemotherapy is not considered the optimal solution in this situation because of the risk of immunosuppression even though in selected groups of patients TPF regimen may bring benefits. Although the MACH-NC meta-analysis of chemotherapy in head and neck cancers did not demonstrate the superiority of induction chemotherapy over concurrent chemoradiotherapy, an induction regimen could be considered for cases with an increased risk of metastasis even in the case of a possible Covid-19 pandemic scenario.
topic head and neck cancer
non-surgical
radiotherapy
chemotherapy
Covid-19
url https://www.mdpi.com/2077-0383/10/4/587
work_keys_str_mv AT camilciprianmirestean newchallengesoftreatmentforlocallyadvancedheadandneckcancersinthecovid19pandemicera
AT andacrisan newchallengesoftreatmentforlocallyadvancedheadandneckcancersinthecovid19pandemicera
AT adinamitrea newchallengesoftreatmentforlocallyadvancedheadandneckcancersinthecovid19pandemicera
AT calinbuzea newchallengesoftreatmentforlocallyadvancedheadandneckcancersinthecovid19pandemicera
AT roxanairinaiancu newchallengesoftreatmentforlocallyadvancedheadandneckcancersinthecovid19pandemicera
AT dragospetruteodoriancu newchallengesoftreatmentforlocallyadvancedheadandneckcancersinthecovid19pandemicera
_version_ 1724284482961276928